Policy

12/08/22

Getting animated about GCEA

Biotech

Policy

10/31/22

Alnylam is doing what the IRA is telling it to do

Biotech

Finance

Policy

09/21/22

Saving money for Medicare by abandoning new drugs for Medicare patients

Biotech

Finance

Policy

08/26/22

Navigating a storm that threatens American biotechnology

Biotech

Policy

08/11/22

The NIH, R&D, and the first mile of the marathon — a conversation with John LaMattina

Biotech

Policy

08/03/22

When life-saving medication should be in aisle three

Biotech

Policy

07/28/22

Innovation and biopharma M&A: feature, not bug

Biotech

Policy

07/13/22

Post-launch, pre-cliff: The R&D Congress ignores

Policy

Biotech

07/08/22

Biotech leaders urge fixes to bad Senate drug deal

Biotech

Policy

06/23/22

How to kill the conversation that makes innovation possible

Biotech

Policy

06/16/22

Right to Try 2.0 doubles down on a bad idea

Biotech

Policy

03/02/22

Commit to counter Russian aggression in Ukraine — join us!

Policy

02/03/22

Muckrakers, a righteous senator, and a gene therapy walk into a bar

Biotech

Culture

Policy

01/20/22

A tale of two healthcare systems

Biotech

Culture

Policy

11/04/21

RA TV: How do we determine what a drug is worth?

Biotech

Policy

08/26/21

RA TV: Aduhelm & Patient-Centered Healthcare Reforms

Biotech

Policy

Science

08/20/21

What happens if President Biden’s drug pricing plan passes?

Biotech

Policy

08/05/21

Biotechnology leadership is too valuable to throw away

Biotech

Policy

07/14/21

When drug prices are a Trojan Horse for other costs, we all lose

Biotech

Policy

09/15/20

The difference between medical debt and ​“moon debt”

Biotech

Culture

Policy